While several companies are working on approaches to stimulating axonal regrowth for conditions caused or characterized by nerve damage, Axerion Therapeutics Inc. believes its NGR receptor decoys will more potently treat conditions such as acute spinal injury by targeting multiple ligands known to prevent the process of regrowth.

Axerion's approach aims to disrupt the natural mechanism that protects the body from haphazard axonal regrowth, which under normal conditions could cause aberrant neural connections.